Kleanthis Gabriel Xanthopoulos - 16 Mar 2026 Form 3 Insider Report for Connect Biopharma Holdings Ltd (CNTB)

Role
Director
Signature
/s/ Lisa Peraza attorney-in-fact for Kleanthis Xanthopoulos
Issuer symbol
CNTB
Transactions as of
16 Mar 2026
Net transactions value
$0
Form type
3
Filing time
16 Mar 2026, 16:44:05 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Xanthopoulos Kleanthis Gabriel Director 3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO /s/ Lisa Peraza attorney-in-fact for Kleanthis Xanthopoulos 16 Mar 2026 0002115875

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CNTB Ordinary Shares 80,000 16 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CNTB Stock Option (Right to Buy) 16 Mar 2026 Ordinary Shares 89,220 $8.16 Direct F1
holding CNTB Stock Option (Right to Buy) 16 Mar 2026 Ordinary Shares 21,269 $4.12 Direct F1
holding CNTB Stock Option (Right to Buy) 16 Mar 2026 Ordinary Shares 28,359 $1.27 Direct F1
holding CNTB Stock Option (Right to Buy) 16 Mar 2026 Ordinary Shares 33,540 $1.18 Direct F1
holding CNTB Stock Option (Right to Buy) 16 Mar 2026 Ordinary Shares 46,512 $1.04 Direct F1
holding CNTB Stock Option (Right to Buy) 16 Mar 2026 Ordinary Shares 60,000 $0.9600 Direct F1
holding CNTB Stock Option (Right to Buy) 16 Mar 2026 Ordinary Shares 60,000 $2.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested and exercisable.
F2 The stock option fully vests and becomes exercisable on March 2, 2027.